Literature DB >> 12823082

Conventional, atypical, and combination antipsychotic prescriptions: a 2-year comparison.

Raymond P Tempier1, Nicole H Pawliuk.   

Abstract

BACKGROUND: The purpose of this study was to determine if there is a relationship between the type of antipsychotic prescribed (conventional, atypical, or a combination) and patients' use of psychiatric services and prescription of adjuvant medications.
METHOD: A chart review of 83 outpatients with long-term psychiatric disorders recorded the type and dosage of psychiatric medications prescribed in 1997-1998 (T1) and 2 years later, in 1999-2000 (T2). Psychiatric service use was also noted during the 2-year follow-up.
RESULTS: Atypical prescriptions increased from 27% (N = 22) to 45% (N = 37) 2 years later. At T2, 35% of patients (N = 29) were prescribed conventionals, and 19% (N = 16) were prescribed a combination of conventionals and atypicals. The mean antipsychotic dosage in chlorpromazine equivalents (546.5 mg/day) increased significantly (p <.05). There was no difference between the 3 groups in their use of psychiatric services or the prescription of adjuvant medications, with the exception of less common prescription of anticholinergics. There was also no difference in psychiatric service use between patients who remained on treatment with combined antipsychotics at T1 and T2 (11%; N = 9) and the rest of the sample. Patients who were switched from one type of antipsychotic to another made more use of psychiatric services, however.
CONCLUSION: Contrary to our expectations, patients prescribed combined antipsychotic types did not make more use of psychiatric services or use more adjuvant medications. The high percentage of patients prescribed a combination may be due to antipsychotic polypharmacy preferences and may represent a very slow crossover from one antipsychotic to another.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12823082     DOI: 10.4088/jcp.v64n0609

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  10 in total

1.  Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia.

Authors:  Kang Sim; Alex Su; Senta Fujii; Shu-Yu Yang; Mian-Yoon Chong; Gabor S Ungvari; Tianmei Si; Eun K Chung; Hin-Yeung Tsang; Yiong H Chan; Stephan Heckers; Naotaka Shinfuku; Chay H Tan
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

Review 2.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

3.  Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999-2002.

Authors:  Gianluca Trifirò; Edoardo Spina; Ovidio Brignoli; Emiliano Sessa; Achille P Caputi; Giampiero Mazzaglia
Journal:  Eur J Clin Pharmacol       Date:  2005-01-22       Impact factor: 2.953

4.  Medication Gaps and Antipsychotic Polypharmacy in Previously Hospitalized Schizophrenia Patients: An Electronic Cohort Study in Three Canadian Provinces.

Authors:  Evyn Peters; Arash Shamloo; Rohit J Lodhi; Gene Marcoux; Kylie Jackson; Shawn Halayka; Lloyd Balbuena
Journal:  Front Psychiatry       Date:  2022-06-15       Impact factor: 5.435

5.  Prescription of psychotropic drugs to patients with schizophrenia: an Italian national survey.

Authors:  Lorenza Magliano; Andrea Fiorillo; Manuela Guarneri; Cecilia Marasco; Corrado De Rosa; Claudio Malangone; Mario Maj
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

6.  Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns.

Authors:  Julie A Kreyenbuhl; Marcia Valenstein; John F McCarthy; Dara Ganoczy; Frederic C Blow
Journal:  Psychiatr Serv       Date:  2007-04       Impact factor: 3.084

7.  Adding antidepressants to antipsychotics for treatment of subsyndromal depressive symptoms in schizophrenia: Impact on positive and negative symptoms.

Authors:  Ipsit V Vahia; Nicole M Lanouette; Shahrokh Golshan; Ian Fellows; Somaia Mohamed; John W Kasckow; Sidney Zisook
Journal:  Indian J Psychiatry       Date:  2013-04       Impact factor: 1.759

8.  Main clinical features in patients at their first psychiatric admission to Italian acute hospital psychiatric wards. The PERSEO study.

Authors:  Andrea Ballerini; Roberto M Boccalon; Giancarlo Boncompagni; Massimo Casacchia; Francesco Margari; Lina Minervini; Roberto Righi; Federico Russo; Andrea Salteri; Sonia Frediani; Andrea Rossi; Marco Scatigna
Journal:  BMC Psychiatry       Date:  2007-01-19       Impact factor: 3.630

9.  Clinical features and therapeutic management of patients admitted to Italian acute hospital psychiatric units: the PERSEO (psychiatric emergency study and epidemiology) survey.

Authors:  Andrea Ballerini; Roberto M Boccalon; Giancarlo Boncompagni; Massimo Casacchia; Francesco Margari; Lina Minervini; Roberto Righi; Federico Russo; Andrea Salteri; Sonia Frediani; Andrea Rossi; Marco Scatigna
Journal:  Ann Gen Psychiatry       Date:  2007-11-05       Impact factor: 3.455

10.  Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use.

Authors:  David Pickar; Jessie Vinik; John J Bartko
Journal:  PLoS One       Date:  2008-09-10       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.